Mr. Ramin Heydarpour reports

YNVISIBLE ANNOUNCES STRATEGIC PARTNERSHIP WITH SAPPHIROS FOR EXCLUSIVE SUPPLY OF E-PAPER DISPLAYS FOR NEXT-GENERATION DIAGNOSTIC DEVICES

Ynvisible Interactive Inc. has received a letter of intent (LOI) from Sapphiros, a privately held consumer diagnostics company, to establish Ynvisible as an exclusive supplier of displays for certain lateral flow and molecular diagnostic tests manufactured by Sapphiros.

Key highlights:

• FDA regulatory pathway under way: clinical studies of Sapphiros's digital lateral flow tests are under way;
• Exclusive supply agreement expected: LOI outlines intention to enter into a three-year exclusive supply agreement;
• Commercial sales in 2026: sales of Ynvisible displays to Sapphiros are under way and will accelerate throughout 2026;
• Expanding medical diagnostics market: this partnership represents Ynvisible's first commercial business in the large and rapidly growing global sector of medical diagnostics, with the company expecting other customers in this market.

To date, Ynvisible has supplied Sapphiros's companies with displays for laboratory testing and continuing clinical studies related to platforms for respiratory and other rapid diagnostic tests, which are designed for both the point-of-care and direct-to-consumer markets. The LOI anticipates continued supply of Ynvisible products in support of the commercial launch of Sapphiros's products, once they receive regulatory approval.

This milestone builds on joint development work that began in 2024, during which Ynvisible engineered customized display solutions for integration into Sapphiros's diagnostics platforms.

Strategic significance

The agreement represents an important step in Ynvisible's strategy to expand into high-volume medical and diagnostic applications, a market that continues to expand as health care systems increasingly adopt decentralized testing and rapid diagnostic technologies. Ynvisible's ultralow-power, thin and flexible displays deliver clear, reliable results and are capable of operating without complex electronics, making Ynvisible's technology particularly well suited for these applications.

"This letter of intent represents an important step toward commercial deployment of Ynvisible's technology in next-generation diagnostic devices," said Ramin Heydarpour, chief executive officer and chairman of Ynvisible. "Our collaboration with Sapphiros demonstrates the performance and scalability of our printed e-paper displays in medical applications. As Sapphiros advances toward regulatory approvals and prepares for commercial launch, this relationship has the potential to create significant high-volume opportunities for Ynvisible."

"Sapphiros is committed to delivering innovations in diagnostics that enable global access and equitable health outcomes to patients and providers alike," said Mark Gladwell, chief executive officer of Sapphiros. "Our partnership with Ynvisible empowers users of our diagnostic devices, whether in their homes, in clinical settings or elsewhere, with clear, visible results, offering confidence in understanding test outcomes."

About Ynvisible Interactive Inc.

Ynvisible is disrupting the low-cost and ultralow-power display industry thanks to the latest advantages in sustainable electronics and roll-to-roll printing production. Ynvisible's printed e-paper displays are ideal for low-power and cost-sensitive applications, such as digital signage, smart monitoring labels for supply chain and logistics, visual indicators for medical and diagnostics, or retail labels and signage. Ynvisible has experience, know-how and intellectual property in electrochromic materials, inks and systems and offers a mix of services, technology and products to brand owners developing smart objects and IoT (Internet of Things) products.

We seek Safe Harbor.